Paluratide - Chugai Pharmaceuticals
Alternative Names: LUNA-18; LUNA18 CapsuleLatest Information Update: 29 Aug 2025
At a glance
- Originator Chugai Pharmaceutical
- Class Antineoplastics; Peptides
- Mechanism of Action Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 30 Jun 2025 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA, Japan (PO) (Chugai Pharmaceuticals pipeline, August 2025)
- 30 Jun 2025 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in USA, Japan (PO) (Chugai Pharmaceuticals pipeline, August 2025)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA (PO, Capsule)